Modified Resistant Maltodextrin Treatment via the Gut-Brain Axis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sleep-wake disorders and neurodegenerative diseases, such as Alzheimer's, do not effectively address sleep disturbances and cognitive decline, and existing hypnotics have undesirable side effects or are not suited for long-term use.
Innovation Solution
Administration of modified resistant maltodextrin to improve sleep quality and reduce symptoms of sleep-wake disorders, including Alzheimer's disease, by altering the gut microbiome and affecting the gut-brain axis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional hypnotics and sleep aids are used to increase sleep time or reduce sleep latency, then sleep duration is improved, but side effects increase and they do not specifically address sleep disorders associated with aging and neurodegenerative diseases
Solution Approach 1:
The patent uses modified resistant maltodextrin as an intermediary substance that acts through the gut-brain axis to indirectly improve sleep quality. Instead of directly administering hypnotics to the brain, the composition modifies gut microbiota which then produces metabolites that cross the blood-brain barrier and exert therapeutic effects, thereby reducing direct side effects while maintaining sleep improvement benefits
Solution Approach 2:
The patent modifies the chemical structure of resistant maltodextrin through specific processing conditions (acid treatment, enzymatic hydrolysis) to create a composition with enhanced prebiotic properties. These parameter changes in the maltodextrin structure enable selective promotion of beneficial gut bacteria that produce sleep-promoting metabolites, thereby improving therapeutic efficacy while reducing side effects
2Reliability
If small molecule drugs or immune therapies are used to block disease-causing proteins in the brain, then disease progression may be slowed, but treatment complexity increases and clinical efficacy remains unproven
Solution Approach 1:
The patent inverts the conventional approach to neurodegenerative disease treatment by not directly targeting brain proteins (amyloid-beta, tau) but instead acting through the gut microbiome. This inverse approach uses oral administration of modified resistant maltodextrin to modulate gut bacteria, which then produce metabolites that cross the blood-brain barrier and reduce neuroinflammation and protein aggregation, simplifying treatment while addressing root causes
Solution Approach 2:
The patent enables the body's own gut microbiota to serve as the therapeutic mechanism. The modified resistant maltodextrin selectively promotes growth of beneficial bacteria that naturally produce neuroprotective metabolites, allowing the body's existing biological systems to perform the therapeutic function rather than requiring complex external drug delivery systems
3Reliability
If therapies are designed to directly target the brain to treat Alzheimer's disease, then central nervous system effects are achieved, but systemic side effects increase and safety concerns arise
Solution Approach 1:
The patent employs gut microbiota metabolites as intermediaries to deliver therapeutic effects to the brain. The modified resistant maltodextrin first acts on gut bacteria, which then produce metabolites (such as short-chain fatty acids and tryptophan derivatives) that cross the blood-brain barrier and exert neuroprotective effects, thereby achieving CNS treatment effectiveness while avoiding direct systemic side effects of conventional brain-targeting drugs
Solution Approach 2:
The patent replaces the mechanical/pharmaceutical approach of directly delivering drugs to the brain with a biological approach using gut-brain axis signaling. Instead of using blood-brain barrier penetrating drugs or invasive delivery systems, the treatment utilizes natural metabolic pathways and microbial-produce d signaling molecules to achieve therapeutic effects with higher safety profiles
4Duration of action of moving object
If existing sleep therapies are used to address sleep disturbances, then some sleep parameters improve, but they fail to address underlying neurodegenerative disease progression and circadian rhythm disruptions
Solution Approach 1:
The patent creates a multi-functional treatment composition that simultaneously addresses multiple aspects of sleep-wake disorders and neurodegenerative diseases. The modified resistant maltodextrin acts as a prebiotic to modify gut microbiota, produces anti-inflammatory metabolites, regulates circadian rhythms through metabolite signaling, and provides neuroprotective effects, thereby improving sleep quality while also addressing underlying disease progression and circadian disruptions in a single versatile therapy
Data Source
AI summary
The invention relates to compositions and methods of treating a sleep-wake disorder or neurodegenerative diseases using modified resistant maltodextrin.